Australie - anglais - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 12.774 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: purified talc; colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; titanium dioxide; polyvinyl alcohol; macrogol 3000 - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 30 microgram; levonorgestrel, quantity: 150 microgram - tablet, film coated - excipient ingredients: povidone; magnesium stearate; lactose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - oral contraception.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - cyproterone acetate,ethinylestradiol -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - raloxifene hydrochloride -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; polysorbate 80; povidone; microcrystalline cellulose; magnesium stearate; glycine; titanium dioxide; hypromellose; carnauba wax; macrogol 400 - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.,raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: maize starch; gelatin; magnesium stearate; hypromellose; macrogol 4000; titanium dioxide; iron oxide red; lactose monohydrate - oral contraception

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: titanium dioxide; iron oxide red; gelatin; maize starch; macrogol 4000; magnesium stearate; hypromellose; lactose monohydrate - oral contraception